Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Philippon, A."'
Autor:
Kyle Porter, Tyler Dickerson, Jennifer Philippon, Kerry A. Rogers, Jennifer A. Woyach, Seema A. Bhat, Daniel Addison, Tracy Wiczer, Avirup Guha, Allyson Waller, Devin Haddad, John C. Byrd, Farrukh T. Awan
Publikováno v:
Blood. 134:1919-1928
Ibrutinib is associated with dramatic efficacy against B-cell malignancies. Yet, ibrutinib is linked with potentially-limiting cardiotoxicity, including emerging reports of profound hypertension. However, the long-term incidence, severity, and impact
Autor:
Ryan Bjordahl, Michelle L. Saetersmoen, Lise Kveberg, Thomas H. Lee, Brian Groff, Jode P Goodridge, Bahram Valamehr, Camille Philippon, Karl-Johan Malmberg, Marianna Vincenti, Svetlana Gaidarova, Dan S. Kaufman, Sajid Mahmood, Frank Cichocki, Artur Cieslar-Pobuda, Hanna Julie Hoel, Matthew Denholtz, Minoru Kanaya, Quirin Hammer, Merete Thune Wiiger, Jeffrey S. Miller, Hui-yi Chu
Publikováno v:
Blood. 136:34-35
Induced pluripotent stem cell (iPSC)-derived natural killer (iNK) cells offer a promising platform for off-the-shelf immunotherapy against cancer. A unique benefit of iPSC-derived immune effector cells is the possibility to perform multiple precision
Autor:
Daniel Addison, Tracy Wiczer, Jennifer Philippon, Allyson Waller, Avirup Guha, Devin Haddad, Tyler Dickerson, Kyle Porter, Kerry A. Rogers, Jennifer A. Woyach, Farrukh T. Awan, John C. Byrd
Publikováno v:
Blood. 132:4423-4423
Background Ibrutinib (IB), a nonselective Bruton's tyrosine kinase inhibitor, is associated with significantly improved disease control rates, progression free, and overall survival in several B-cell malignancies. Yet, IB's nonselective actions may r
Autor:
Dominique Bordessoule, Stephane Moreau, Nathalie Gachard, Sophie Lefort, Pascal Turlure, Jean Feuillard, Stephane Girault, Liliane Remenieras, Celine Philippon, Marie-Pierre Gourin, Mohamed Touati
Publikováno v:
Blood. 114:4283-4283
Abstract 4283 Introduction In recent area, management of CML has benefited from important changes with the development of targeted therapies and monitoring therapeutic response. Respect of good practices in rural countries, geographically isolated as